333 completed, 117 terminated, 77 recruiting, 54 active not recruiting. 678 Phase 1, 224 Phase 2.
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2027-03-26 | 2026-10-20 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332 - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Not yet recruiting | Istituto Oncologico Veneto IRCCS | 14 | 2027-01-31 | 2026-11-03 |
| Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-07-27 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Axatilimab + CAR-T for High-Risk Lymphoma Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 29 | 2026-12-31 | 2026-10-16 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0920 - Diffuse Large B-Cell Lymphoma, B-cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-12-11 | 2026-10-21 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) REGN9220, Odronextamab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 36 | 2026-12-07 | 2026-10-21 |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0050 - Diffuse Large B-Cell Lymphoma, B-Cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-11-30 | 2026-10-19 |
| Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine - Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | Phase 1 | Recruiting | Weill Medical College of Cornell University | 32 | 2026-11-01 | 2026-10-26 |
| HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV Elranatamab (Elra) - Plasmablastic Lymphoma, HIV | Phase 1 | Recruiting | University of Illinois at Chicago | 17 | 2026-10-21 | 2026-10-26 |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-09-01 | 2026-10-09 |
| A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma BL-M08D1, Rituximab, Gemcitabine Hydrochloride - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 204 | 2026-09-01 | 2026-09-14 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma 7×19-THEMIS CAR-T cells - Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 70 | 2026-09-01 | 2026-08-26 |
| A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies Lacutoclax+Rocbrutinib - Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 92 | 2026-07-14 | 2026-07-30 |
Showing 20 of 678. Sign in to see all of them.
Lymphoma, Follicular (388) · Lymphoma, Mantle-Cell (363) · Lymphoma, Non-Hodgkin (325) · Leukemia, Lymphocytic, Chronic, B-Cell (294) · Lymphoma, B-Cell, Marginal Zone (273) · Burkitt Lymphoma (256) · Lymphoma (238) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (232) · Lymphoma, Large-Cell, Immunoblastic (196) · Hodgkin Disease (177) · Waldenstrom Macroglobulinemia (131) · Lymphoma, Large-Cell, Anaplastic (125) · Lymphoma, T-Cell, Cutaneous (121) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (116)
Hemic and Lymphatic Diseases (678) · Neoplasms by Histologic Type (674) · Lymphatic Diseases (672) · Immunoproliferative Disorders (671) · Immune System Diseases (670) · Lymphoproliferative Disorders (665) · Neoplasms (630) · Lymphoma, B-Cell (601) · Lymphoma (440) · Hematologic Diseases (371) · Lymphoma, Non-Hodgkin (353) · Pathological Conditions, Signs and Symptoms (353) · Pathologic Processes (352) · Disease Attributes (347) · Leukemia, Lymphoid (327)
Rituximab (119) · Cyclophosphamide (106) · Prednisone (47) · Etoposide (45) · Vincristine (44) · Doxorubicin (43) · Lenalidomide (40) · fludarabine (33) · fludarabine phosphate (33) · ibrutinib (28) · Filgrastim (27) · Peripheral Blood Stem Cell Transplantation (27) · Gemcitabine (25) · Carboplatin (23) · venetoclax (20)
National Cancer Institute (NCI) (79) · Fred Hutchinson Cancer Center (20) · City of Hope Medical Center (18) · Memorial Sloan Kettering Cancer Center (14) · Mayo Clinic (13) · M.D. Anderson Cancer Center (12) · Masonic Cancer Center, University of Minnesota (11) · Northwestern University (11) · National Institutes of Health Clinical Center (CC) (10) · Novartis Pharmaceuticals (9) · Case Comprehensive Cancer Center (8) · Celgene (8) · Hoffmann-La Roche (8) · Incyte Corporation (8) · Jonsson Comprehensive Cancer Center (7)
United States (523) · China (71) · France (54) · Spain (53) · United Kingdom (49) · Italy (48) · Australia (39) · Canada (37) · Germany (35) · South Korea (31) · Japan (23) · Poland (19) · Belgium (18) · Netherlands (18) · Israel (15)
Ajay Gopal (6) · Roger Strair, MD, PhD (4) · Shivaani Kummar, MD (4) · Claudio G. Brunstein, MD, PhD (3)
PMID 34515338, PMID 34398557, PMID 40802906, PMID 19949018, PMID 20028764, PMID 22002018, PMID 31527168, PMID 32499241, PMID 34310745, PMID 34493319, PMID 36375120, PMID 39319495, PMID 10552943, PMID 10632319, PMID 10764422, PMID 11410496, PMID 11756154, PMID 12171484, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15570084, PMID 16135477, PMID 16731764, PMID 17119113, PMID 17312328, PMID 17515574, PMID 17947483, PMID 18327587, PMID 18463792, PMID 18470481, PMID 18974373, PMID 19139736, PMID 19179301, PMID 19238148, PMID 19451403, PMID 19451441, PMID 19652067, PMID 19789320, PMID 20952687, PMID 21247755, PMID 21403127, PMID 21498721, PMID 22259028, PMID 22430088, PMID 22775314, PMID 22965964, PMID 23256542, PMID 23393050, PMID 23592273
P30CA033572 (12), 2023 (10), 2016 (9), P30CA015083 (9), P30CA015704 (9), 2015 (8), 2017 (6), 2025 (6), U01CA069912 (6), U01CA076576 (6), 2018 (5), P30CA016058 (5), P30CA016672 (5), P50CA107399 (5), U01CA062487 (5)